&lt;p&gt;Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring &lt;em&gt;EGFR&lt;/em&gt; G719A/V769M Complex Mutation&lt;/p&gt;

Simionato, Francesca; Calvetti, Lorenzo; Cosci, Marco; Scarparo, S.; Aprile, Giuseppe

doi:10.2147/ott.s280933

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 34 ] 72 Male G719X + S768I Osimertinib GR Simionato et al . [ 35 ] 69 Female G719A + V769M Osimertinib GR Juan et al . [ 36 ] 43 Female 19-Del + T790M Chemotherapy PD He et al .…”

Section: Discussionmentioning

confidence: 99%

An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report

Boukansa,

Mouhrach,

El Agy

et al. 2024

J Med Case Reports

View full text Add to dashboard Cite

Background In the current treatment landscape for non-small cell lung cancers, epidermal growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established treatment option for patients with advanced or metastatic disease. This is particularly true for those with commonly occurring epidermal growth factor receptor mutations. However, the therapeutic efficacy of these agents for so-called rare epidermal growth factor receptor mutations, and in particular those characterized by a high degree of complexity, such as double mutations, remains a subject of clinical uncertainty. Case presentation In this context, we present the case of a 64-year-old man of Moroccan descent, a lifelong non-smoker, diagnosed with metastatic non-small cell lung cancer characterized by a complex epidermal growth factor receptor mutation encompassing L858R and S768I. The patient subsequently underwent afatinib-based treatment, showing notable clinical results. These included a remarkable overall survival of 51 months, with a median progression-free survival of more than 39 months. Conclusions This case report is a compelling testimony to the evolving therapeutic landscape of non-small cell lung cancers, providing valuable insight into the potential therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in the realm of rare and complex epidermal growth factor receptor mutations.

show abstract

“…[ 34 ] 72 Male G719X + S768I Osimertinib GR Simionato et al . [ 35 ] 69 Female G719A + V769M Osimertinib GR Juan et al . [ 36 ] 43 Female 19-Del + T790M Chemotherapy PD He et al .…”

Section: Discussionmentioning

confidence: 99%